ANDA 75719, held by Ivax Sub Teva Pharms. Sertraline Hydrochloride.
As of Nov 16, 2026, ANDA 75719 (Sertraline Hydrochloride), held by Ivax Sub Teva Pharms, was first approved by FDA on Jun 30, 2006, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 30, 2006 | Original application | Approved |
| Sertraline HydrochlorideEQ 50MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Sertraline HydrochlorideEQ 100MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Sertraline HydrochlorideEQ 25MG BASE · tablet;oral | Sertraline Hydrochloride | Discontinued |
| Aug 28, 2008 | Supplement 4Labeling | Approved | None posted |
| Jan 9, 2008 | Supplement 1Labeling | Approved | None posted |
| Jan 9, 2008 | Supplement 2Labeling | Approved | None posted |
| Jan 9, 2008 | Supplement 3Labeling | Approved | None posted |
| Jun 30, 2006 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters